

# Allen Peng BSc (Pharm), MSc (Clin Pharm), MPH

allen.peng08@gmail.com | 443-801-2670 | linkedin.com/in/allen-peng-yl/

Health economist and with 8 years of experience across a national health technology assessment (HTA) agency and global pharmaceutical companies. Proven ability to lead cross-functional teams and align stakeholders across medical, health economics & outcomes research (HEOR), and commercial functions to drive market access strategy. Skilled in cost-effectiveness analysis (CEA), budget impact modeling, and real-world evidence generation using SAS and R, with a strong track record of informing payer decisions and shaping policy. Recognized with *Pfizer's 2023 Global Best Practice Award* for accelerating reimbursement and pricing approvals.

## **WORKING EXPERIENCE**

### **Healthcare Analyst Intern | MSQ Ventures**

SEPT. 2025 – PRESENT

- Conducted scientific and market due diligence on 50+ biotech firms, including T cell therapy landscape analysis for Swarm Oncology, to identify cross-border partnership and investment opportunities
- Developed 10+ pitch decks and pipeline evaluations supporting in/out-licensing and fundraising projects across the U.S., China, and Europe
- Analyzed global biopharma market and capital trends, summarizing insights that informed prospect targeting and client engagement strategies

### **Market Access Manager | Pfizer**

AUG. 2022 – MAY 2024

- Awarded *2023 Global Pfizer Best Practice - Access Acceleration* for CIBINQO®
  - Led access strategy that achieved reimbursement and pricing approval 6 months ahead of standard timeline, through close collaboration with global HEOR, commercial, medical, and public affairs teams
  - Secured listing price premiums through cost-effectiveness modeling, demonstrating compelling economic value to the national payer
- Led cross-functional and external stakeholder alignment across regulatory, medical, commercial, and advocacy partners, ensuring launch readiness and public awareness for new immunology products and PCV20
- Expanded reimbursement scope of atopic dermatitis by crafting value propositions that integrated unmet needs and clinical evidence, successfully negotiating with the national payer to broaden patient access
- Developed simulation models to assess financial impact of biosimilar-favoring policies, enabling proactive mitigation strategies to protect branded biologics portfolio positioning

### **Senior Patient Access Specialist | Novartis**

APR. 2020 – AUG. 2022

- Developed CEA and pricing models across cardiovascular and respiratory portfolios, including Enerzair®, where the strategy led to a 2% price markup approved by the national payer
- Conducted real-world outcomes research using Taiwan's nationwide claims database (23 million lives) to demonstrate clinical benefits of Entresto® in heart failure care
- Organized and led *International HTA Workshop* (100+ attendees), including Director-General and senior officers from the national payer and HTA agency, to strengthen policy dialogue and payer engagement
- Co-authored policy white papers on cardiovascular disease management, enhancing payer education and disease awareness - "*Shaping Cardiovascular Disease Access Policy Landscape*"

### **HTA Researcher in Economic Team | Center for Drug Evaluation**

MAR. 2017 – APR. 2020

- Conducted 20+ CEAs and budget impact analysis annually and authored HTA reports for new drug reimbursement applications, informing payer decisions and enabling access for 600,000+ patients
- Developed Horizon Scanning system to support national payer in proactive budget planning and allocation
- Accelerated pneumococcal vaccine policy implementation in high-risk populations by evaluating clinical outcomes and cost-effectiveness, informing national rollout decisions
- Facilitated *Pharmacoeconomics Workshops* for pharmaceutical professionals, delivering theoretical and hands-on training on CEA model development using TreeAge and Excel
- Published HEOR studies and presented findings at international conferences (HTAsiaLink, ISPOR Asia), showcasing analytical and effective scientific communication.

### **Assistant Researcher | Kaohsiung Chang Gung Memorial Hospital**

SEPT. 2016 – MAR. 2017

- Performed real-world data analysis using SAS on hospital electronic medical records (EMR), including data cleaning, regression modeling, and statistical interpretation

- Authored a propensity-score matched cohort study examining renal protection effects of medications hyperuricemia patients, contributing to evidence-based clinical recommendations
- Conducted EQ-5D interviews with pediatric CKD patients as part of a quality-of-life study, also leading IRB submission preparations and developing study protocol to ensure ethical and methodological rigor
- Participated in the national EQ-5D-5L validation study in Taiwan (Lin et al., 2018), assisting with survey implementation and data quality monitoring across diverse population groups

## **EDUCATION**

**Master of Public Health | Johns Hopkins Bloomberg School of Public Health** JULY 2024 – MAY 2025

- Concentration: Health Systems and Policy | Certificate: Public Health Economics
- Selected Coursework & Training:
  - Pharmacoeconomics: RCTs, Observational Studies, Meta-analysis, Systematic Review
  - Biostatistics & Tools: R, SAS, SPSS
  - Policy & Systems: U.S. Healthcare System, Health Policy, Epidemiology of Infectious Disease, Health Advocacy
- Research Project: *“Specialty Drugs Cost, Utilization and Policy Evaluation”*
- Capstone Field Project (Lao PDR): *“Private Pharmacies as First Points of Healthcare Access: Participatory Action Research for Good Pharmacy Practice Implementation in the Lao PDR”*
- Practicum (Baltimore, MD): *“Healthcare for the Homeless”* – Designed questionnaires, conducted interviews and co-developed practical solutions to streamline referral pathways
- Leadership: Secretary of the Anna Baetjer Society for Public Health Practice

**Master of Science in Clinical Pharmacy | Kaohsiung Medical University** SEPT. 2014 – JUNE 2016

- Thesis: *“The effect of febuxostat and other urate-lowering agents on uric acid management and renal outcome in patients with chronic kidney disease”*

**Bachelor of Science in Pharmacy | Kaohsiung Medical University** SEPT. 2010 – JUNE 2014

- Licensed Pharmacist, Taiwan Ministry of Health and Welfare (July 2014)

## **SKILLS**

**Health Economics & Outcomes Research (HEOR):** CEA, BIA, health utility measurement (EQ-5D), RWE generation, Outcomes research design, HTA submission strategy

**Study Design & Implementation:** Protocol development, IRB submission, Patient-reported outcome (PRO) study implementation, Pediatric patient interviews, Mixed-methods research (quantitative + qualitative)

**Stakeholder Engagement & Communication:** Payer and HCP engagement, Policy communication, Workshop facilitation, Scientific writing and presentation

**Data Analytic Software & Modeling:** SAS, R, Excel, TreeAge, SPSS, NVivo, Python, SQL

**Languages:** Mandarin Chinese (native), English (fluent; TOEFL 100)

## **SELECTED PUBLICATIONS & PRESENTATIONS**

### ***Journal***

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with CKD. *Sci Rep.* 2020 Jul 1;10(1):10734. [\[LINK\]](#)

The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice. *PLoS One.* 2019 Aug 26;14(8):e0221504. [\[LINK\]](#)

Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. *Curr Med Res Opin.* 2020 Oct;36(10):1619-1626. [\[LINK\]](#)

### ***Conference***

Cost-Utility Analysis of Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients in Taiwan. 2019 8<sup>th</sup> HTAsiaLink Annual Conference, Apr. 22-28, 2019, Korea (Oral Presentation)

Impact of Adoption of a New Drug on the Trends in Utilization Patterns Changes and Pharmaceutical Expenditure- An Example of Urate-Lowering Therapy. 2016 ISPOR 7<sup>th</sup> Asia-Pacific Conference, Sept. 3-5, 2016, Singapore (Podium)

A Meta-analysis & Systematic Review: The Effectiveness of Urate-lowering and Renoprotection between Febuxostat and Allopurinol among Hyperuricemia Patients with Chronic Kidney Disease. 2015 13<sup>th</sup> Taiwan Society of Health-System Pharmacists (TSHP), Nov. 8, 2015, Taiwan (Poster Presentation)